OAM
SWTX

Oppenheimer Asset Management’s SpringWorks Therapeutics SWTX Stock Holding History

Oppenheimer Asset Management’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,526
Closed -$597K – 1202
2025
Q1 		$597K Buy
13,526
+967
+8% +$44.5K 0.01% 809
2024
Q4 		$454K Sell
12,559
-837
-6% -$29.2K 0.01% 886
2024
Q3 		$429K Sell
13,396
-172
-1% -$6.43K 0.01% 913
2024
Q2 		$511K Buy
13,568
+3,892
+40% +$164K 0.01% 854
2024
Q1 		$476K Sell
9,676
-698
-7% -$32.3K 0.01% 848
2023
Q4 		$379K Sell
10,374
-1,267
-11% -$33.1K 0.01% 930
2023
Q3 		$269K Sell
11,641
-47
-0.4% -$1.28K ﹤0.01% 982
2023
Q2 		$306K Buy
+11,688
New +$307K ﹤0.01% 965
2022
Q4 		– Sell
-8,310
Closed -$237K – 1178
2022
Q3 		$237K Sell
8,310
-372
-4% -$10.7K ﹤0.01% 1012
2022
Q2 		$214K Sell
8,682
-225
-3% -$8.23K ﹤0.01% 1060
2022
Q1 		$503K Buy
8,907
+660
+8% +$37.8K 0.01% 915
2021
Q4 		$511K Buy
8,247
+3,302
+67% +$219K 0.01% 955
2021
Q3 		$314K Buy
+4,945
New +$381K ﹤0.01% 1047

Other funds holding SWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Oppenheimer Asset Management's SWTX Position: Q2 2025 in Review

Oppenheimer Asset Management sold out of SpringWorks Therapeutics (SWTX) in Q2 2025, closing a stake of 13,526 shares — an estimated $597K sold.

Oppenheimer Asset Management first reported a position in SWTX in Q3 2021 and held it in 13 quarters. The position peaked at $597K in Q1 2025. 223 funds tracked by Wall St. Rank hold SWTX as of Q2 2025.

  • Oppenheimer Asset Management reported no remaining SpringWorks Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Oppenheimer Asset Management sold 13,526 SpringWorks Therapeutics shares in Q2 2025, an estimated $597K.
  • Oppenheimer Asset Management first reported a position in SpringWorks Therapeutics in Q3 2021 and held it in 13 quarters.
  • Oppenheimer Asset Management's SpringWorks Therapeutics position peaked at $597K in Q1 2025.
  • 223 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2025.

Based on Oppenheimer Asset Management's 13F filing for Q2 2025, filed 31 Jul 2025.